Who Paid My Doc
Rytelo
Drug Myelodysplastic Syndrome
NDC 82959-112-01
General payments
$1,047,307
Research payments
$20,587
Through program year 2025, $1,047,307 in general payments and $20,587 in research payments were reported against Rytelo (Myelodysplastic Syndrome).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $989,011 | 6,639 |
| 2024 | General | $58,296 | 436 |
| 2024 | Research | $20,587 | 16 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 89 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
7,075 general · 16 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.